Exelixis Inc Deferred Tax Assets, Operating Loss Carryforwards
Exelixis Inc (EXEL) had Deferred Tax Assets, Operating Loss Carryforwards of $39.91 million as of 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-10
- 2026-01-02: Deferred Tax Assets, Operating Loss Carryforwards $39.91M.
- 2025-01-03: Deferred Tax Assets, Operating Loss Carryforwards $39.88M.
- 2023-12-29: Deferred Tax Assets, Operating Loss Carryforwards $29.51M.
- 2022-12-30: Deferred Tax Assets, Operating Loss Carryforwards $33.63M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2026-01-02 | $39.91M 10-K · filed 2026-02-10 |
| 2025-01-03 | $39.88M 10-K · filed 2026-02-10 |
| 2023-12-29 | $29.51M 10-K · filed 2025-02-11 |
| 2022-12-30 | $33.63M 10-K · filed 2024-02-06 |
| 2021-12-31 | $17.99M 10-K · filed 2023-02-07 |
| 2021-01-01 | $37.45M 10-K · filed 2022-02-18 |
| 2020-01-03 | $65.13M 10-K · filed 2021-02-11 |
| 2018-12-28 | $146.70M 10-K · filed 2020-02-25 |
| 2017-12-29 | $244.21M 10-K · filed 2019-02-22 |
| 2016-12-31 | $471.33M 10-K · filed 2017-02-27 |
| 2016-12-30 | $471.33M 10-K · filed 2018-02-26 |
| 2015-12-31 | $464.50M 10-K · filed 2017-02-27 |
| 2014-12-31 | $446.34M 10-K · filed 2016-02-29 |
| 2013-12-31 | $358.37M 10-K · filed 2015-03-02 |
| 2012-12-31 | $374.20M 10-K · filed 2014-02-20 |
| 2011-12-31 | $318.64M 10-K · filed 2013-02-21 |
| 2010-12-31 | $273.39M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |